Back to Search
Start Over
213MO Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)
- Source :
- Annals of Oncology. 33:S635
- Publication Year :
- 2022
- Publisher :
- Elsevier BV, 2022.
- Subjects :
- Oncology
Hematology
Subjects
Details
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- OpenAIRE
- Journal :
- Annals of Oncology
- Accession number :
- edsair.doi...........6696e347d2f6ed1cecfc97a421f2f21c
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.07.252